185 related articles for article (PubMed ID: 35985932)
1. HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
Bergamino MA; López-Knowles E; Morani G; Tovey H; Kilburn L; Schuster EF; Alataki A; Hills M; Xiao H; Holcombe C; Skene A; Robertson JF; Smith IE; Bliss JM; Dowsett M; Cheang MCU;
EBioMedicine; 2022 Sep; 83():104205. PubMed ID: 35985932
[TBL] [Abstract][Full Text] [Related]
2. Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Gao Q; López-Knowles E; Cheang MCU; Morden J; Ribas R; Sidhu K; Evans D; Martins V; Dodson A; Skene A; Holcombe C; Mallon E; Evans A; Bliss JM; Robertson J; Smith I; Martin LA; Dowsett M;
Breast Cancer Res; 2019 Dec; 22(1):2. PubMed ID: 31892336
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers.
Schuster EF; Lopez-Knowles E; Alataki A; Zabaglo L; Folkerd E; Evans D; Sidhu K; Cheang MCU; Tovey H; Salto-Tellez M; Maxwell P; Robertson J; Smith I; Bliss JM; Dowsett M
Nat Commun; 2023 Jul; 14(1):4017. PubMed ID: 37419892
[TBL] [Abstract][Full Text] [Related]
4. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Cancer Sci; 2014 Jan; 105(1):81-8. PubMed ID: 24118529
[TBL] [Abstract][Full Text] [Related]
5. Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
Lopez-Knowles E; Detre S; Hills M; Schuster EF; Cheang MCU; Tovey H; Kilburn LS; Bliss JM; Robertson J; Mallon E; Skene A; Evans A; Smith I; Dowsett M
Breast Cancer Res; 2022 Sep; 24(1):61. PubMed ID: 36096872
[TBL] [Abstract][Full Text] [Related]
6. Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
Bliss JM; Tovey H; Evans A; Holcombe C; Horgan K; Mallon E; Vidya R; Skene A; Dodson A; Hills M; Detre S; Zabaglo L; Banerji J; Kilburn L; Morden JP; Robertson JFR; Smith I; Dowsett M;
Breast Cancer Res; 2023 Apr; 25(1):39. PubMed ID: 37046348
[TBL] [Abstract][Full Text] [Related]
7. Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
Ju J; Du F; Gao SL; Si YR; Hu NL; Liu DX; Wang X; Yue J; Zheng FC; Kang YK; Yang ZX; Ma F; Xu BH; Yuan P
Breast Cancer Res Treat; 2022 Jul; 194(2):221-230. PubMed ID: 35699854
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
9. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Arnedos M; Drury S; Afentakis M; A'Hern R; Hills M; Salter J; Smith IE; Reis-Filho JS; Dowsett M
Ann Oncol; 2014 Mar; 25(3):605-610. PubMed ID: 24525703
[TBL] [Abstract][Full Text] [Related]
10. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
[TBL] [Abstract][Full Text] [Related]
11. Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
Laible M; Hartmann K; Gürtler C; Anzeneder T; Wirtz R; Weber S; Keller T; Sahin U; Rees M; Ramaswamy A
BMC Cancer; 2019 Jul; 19(1):694. PubMed ID: 31307414
[TBL] [Abstract][Full Text] [Related]
12. High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.
Endo Y; Toyama T; Takahashi S; Sugiura H; Yoshimoto N; Iwasa M; Kobayashi S; Fujii Y; Yamashita H
Int J Clin Oncol; 2011 Oct; 16(5):512-8. PubMed ID: 21431343
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology.
Karlsson E; Appelgren J; Solterbeck A; Bergenheim M; Alvariza V; Bergh J
Eur J Cancer; 2014 Nov; 50(17):2916-24. PubMed ID: 25241230
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
Smith I; Robertson J; Kilburn L; Wilcox M; Evans A; Holcombe C; Horgan K; Kirwan C; Mallon E; Sibbering M; Skene A; Vidya R; Cheang M; Banerji J; Morden J; Sidhu K; Dodson A; Bliss JM; Dowsett M
Lancet Oncol; 2020 Nov; 21(11):1443-1454. PubMed ID: 33152284
[TBL] [Abstract][Full Text] [Related]
15. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Iorfida M; Mazza M; Balduzzi A; Veronesi P; Luini A; Intra M; Goldhirsch A; Colleoni M
Ann Oncol; 2013 Mar; 24(3):661-8. PubMed ID: 23022996
[TBL] [Abstract][Full Text] [Related]
16. Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.
Anderson H; Hills M; Zabaglo L; A'hern R; Leary AF; Haynes BP; Smith IE; Dowsett M
Ann Oncol; 2011 Aug; 22(8):1770-6. PubMed ID: 21285137
[TBL] [Abstract][Full Text] [Related]
17. Association between breast cancer subtypes and response to neoadjuvant anastrozole.
Dunbier AK; Anderson H; Ghazoui Z; Salter J; Parker JS; Perou CM; Smith IE; Dowsett M
Steroids; 2011 Jul; 76(8):736-40. PubMed ID: 21447351
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of preoperative
Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
[TBL] [Abstract][Full Text] [Related]
20. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
